Why Eli Lilly’s Insulin Price Cap Announcement Matters
Insulin manufacturer Eli Lilly follows the government’s lead with a $35 price cap. Will manufacturers follow suit?
Addressing chronic diseases such as heart disease, stroke, cancer, and diabetes, and their relationship to health inequity
Explore the latest public health research and insights about noncommunicable diseases.
Insulin manufacturer Eli Lilly follows the government’s lead with a $35 price cap. Will manufacturers follow suit?
Looking for prominent public health experts in the field of noncommunicable diseases? They’re here at the Bloomberg School of Public Health.
Joshua Sharfstein, MD, works to develop and promote public health strategies, healthcare payment approaches, and regulatory policies that advance health and equity.
Elizabeth Selvin, PhD '04, MPH, leads research at the nexus of epidemiology and clinical practice, focusing on diagnosing and screening for diabetes and prediabetes.